Precigen Inc. (PGEN)$4.24
Market Cap: 448.65 MCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Precigen Inc. (PGEN).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-5.7x
EV/FCF, N/A FCF yield
Quality
-219.7%
ROIC, -927.6% FCF margin
Growth
-21.3%
5Y sales (revenue) CAGR
Balance sheet
4.5x
Debt/equity, 3.1x current ratio
Superinvestors
1
Top: Samantha McLemore (2.6%)
Strengths to research
- 10 annual periods are available for trend analysis.
Watchouts
- Free cash flow margin is negative at -927.6%.
- Five-year revenue trend is negative at -21.3%.
- Debt/equity is high at 4.5x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for PGEN.
Grade F
1
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| PGEN Target | Precigen Inc. | $448.7M | -3.1x | -5.7x | -219.7% | -21.3% | -927.6% | N/A | N/A | N/A |
| ORIC | ORIC Pharmaceuticals Inc. | $405.2M | -5.7x | -3.2x | -33.7% | N/A | N/A | N/A | N/A | N/A |
| DNA | Ginkgo Bioworks Holdings Inc. | $402.4M | -1.5x | -1.3x | -0.1% | 17.3% | -105.0% | N/A | N/A | N/A |
| TRVI | Trevi Therapeutics Inc. | $667.1M | -44.2x | -15.4x | -23.3% | N/A | N/A | N/A | N/A | N/A |
| NUVB | Nuvation Bio Inc. | $808.4M | -7.9x | -4.0x | -58.0% | N/A | -275.7% | N/A | N/A | N/A |
| RCKT | Rocket Pharmaceuticals Inc. | $838.3M | -1.5x | -4.0x | -80.5% | N/A | N/A | N/A | N/A | N/A |
| PHVS | Pharvaris NV | $1.0B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| INBX | Inhibrx | $178.5M | -11.2x | -0.4x | -1752.2% | N/A | -9986.5% | N/A | N/A | N/A |
| DMAC | DiaMedica Therapeutics Inc. | $171.4M | N/A | -5.4x | -58.4% | N/A | N/A | N/A | N/A | N/A |
Financial Charts
No financial data available for PGEN (annual).
1 superinvestors own PGEN
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Samantha McLemore Patient Capital Management | 17,817,387 | $69M | 2.57% | 0.0% |